GLP-1激动剂与DPP-4抑制剂在血液透析患者中的死亡率比较:目标试验模拟
本研究利用2011至2021年美国肾脏数据系统和医保索赔数据,模拟目标试验,比较血液透析患者中GLP-1激动剂与DPP-4抑制剂使用者的死亡率。结果显示,意向治疗分析中全因死亡风险无显著差异(HR 0.98,95%CI 0.89-1.07),但符合方案分析中持续使用GLP-1激动剂与全因死亡风险降低相关(HR 0.81,95%CI 0.68-0.96),且GLP-1停药率较高。
要点
- 意向治疗分析中GLP-1激动剂未显著降低血液透析患者全因死亡风险。
- 持续使用GLP-1激动剂与全因死亡风险降低相关,但停药率高。
- GLP-1激动剂组胃肠道症状风险轻度升高。
核心结论
- 在血液透析患者中,启动GLP-1激动剂对比DPP-4抑制剂在意向治疗分析中未显著降低全因死亡率。
- 持续使用GLP-1激动剂与改善生存相关,但治疗潜力可能受药物停药限制。
研究设计与样本
- 研究利用2011至2021年美国肾脏数据系统和医保索赔数据,模拟目标试验,纳入在中心血液透析存活≥90天后启动药物的新使用者。
- 共识别3671名GLP-1激动剂使用者和12039名DPP-4抑制剂使用者,采用逆概率治疗加权和Cox比例风险模型估计风险比。
主要发现
- 意向治疗分析中,GLP-1激动剂对比DPP-4抑制剂的全因死亡HR为0.98(95%CI 0.89-1.07),心血管死亡HR为1.06(95%CI 0.92-1.23),感染死亡HR为0.83(95%CI 0.54-1.26)。
- 符合方案分析中,全因死亡HR为0.81(95%CI 0.68-0.96),心血管死亡HR为0.89(95%CI 0.69-1.13),感染死亡HR为0.65(95%CI 0.37-1.14)。
- GLP-1激动剂组1年累积停药率为53%,DPP-4抑制剂组为42%;胃肠道症状HR为1.11(95%CI 1.02-1.20)。
临床怎么用
- 在血液透析患者中处方GLP-1激动剂时,应关注持续用药和耐受性,以可能实现生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The comparative effectiveness of glucagon-like peptide-1 (GLP-1) agonists (GLP-1s) versus dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4s) in hemodialysis is unknown. METHODS: Using 2011 to 2021 US Renal Data System and Medicare claims data, we emulated a target trial comparing new users of GLP-1s versus DPP-4s with patients who survived ≥ 90 days on in-center hemodialysis before medication initiation. We used inverse probability of treatment weighting (IPTW) and Cox proportional hazards models to estimate hazard ratios (HRs). RESULTS: We identified 3671 GLP-1 and 12,039 DPP-4 users. After IPTW, mean age was 63 years, 52% male, 63% White, and mean body mass index was 31 kg/m2. The median (interquartile interval) follow-up was 1.5 (0.6-2.9) years. In intention-to-treat analysis, the all-cause mortality HR for GLP-1s (vs. DPP-4s) was 0.98 (95% confidence interval [CI]: 0.89-1.07); cardiovascular mortality HR was 1.06 (95% CI: 0.92-1.23); infection mortality HR: 0.83 (95% CI: 0.54-1.26). In per-protocol analysis with censoring at medication discontinuation, the all-cause mortality HR was 0.81 (95% CI: 0.68-0.96), and the 1-year cumulative incidence of discontinuation was 53% for GLP-1s versus 42% for DPP-4s. The cardiovascular mortality HR was 0.89 (95% CI: 0.69-1.13); infection mortality HR 0.65 (95% CI: 0.37-1.14). Finally, the gastrointestinal symptom HR was 1.11 (95% CI: 1.02-1.20). CONCLUSION: GLP-1 (vs. DPP-4) initiation was not associated with reduced mortality in intention-to-treat analysis, but continuous use was associated with improved survival. The therapeutic potential of GLP-1s among patients receiving hemodialysis may be limited by medication discontinuation.
引用
- Le D, Kilpatrick M, Kraft WK, et al. Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis. Kidney Int Rep. 2026. PMID: 42381765. doi:10.1016/j.ekir.2026.106618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。